Nodular Fasciitis With Malignant Morphology and a COL6A2–USP6 Fusion: A Case Report (of a 10-Year-old Boy)

Tess Tomassen, Cees van de Ven, MD, PhD; Jakob Anninga, MD, PhD; Christian Koelsche, MD, PhD; Laura S. Hiemcke-Jiwa, MD, PhD; Simone ter Horst, MD, PhD; Wendy W. de Leng, PhD; Franck Tirode, PhD; Marie Karanian, MD; and Uta Flucke, MD, PhD

Abstract
Nodular fasciitis is usually a benign lesion genetically characterized by ubiquitin-specific protease 6 (USP6) rearrangements. We present a case of a 10-year-old boy with a 1.5-week history of a painless mass on the right chest wall, which was excised. A histomorphologically malignant tumor with pronounced pleomorphism, atypical mitotic figures, and a myoid immunophenotype was observed. The methylation profile was consistent with nodular fasciitis and fluorescence in situ hybridization confirmed USP6 rearrangement. Using Archer Fusion Plex (Sarcoma Panel) and RNA sequencing, a collagen, type VI, alpha 2 (COL6A2)–USP6 gene fusion was subsequently identified. Furthermore, DNA clustering analysis also showed a match with nodular fasciitis. During the follow-up of 22 months, no recurrence or metastasis occurred. In conclusion, we describe a clinically benign, histomorphologically malignant mesenchymal neoplasm with a myoid immunophenotype, and a genetic and epigenetic profile consistent with nodular fasciitis. In such cases, molecular analysis is a useful adjunct to avoid unnecessary overtreatment.

Keywords
pleomorphic sarcoma, nodular fasciitis, COL6A2–USP6, fusion gene, clustering, DNA-cluster analysis, methylation profiling

Introduction
Nodular fasciitis (NF) is a benign rapidly growing myofibroblastic lesion, usually arising in the superficial soft tissue of young adult patients. Involvement of the upper limbs and trunk is most common but localization at any other site is possible. The identification of ubiquitin-specific protease 6 (USP6) rearrangement in over 90% of NF cases has not only supported its clonal neoplastic nature but also serves as a reliable diagnostic confirmation in respective lesions, especially when small biopsies are taken, to avoid overtreatment. Malignant behavior of NF has been reported exceptionally in cases with classical morphology. However, according to our knowledge, NF cases with pleomorphic sarcoma-like morphology are hitherto not described.

In this report, we present an unusual case of a clinically benign but morphologically malignant lesion in a 10-year-old boy, which is genetically and epigenetically consistent with NF.

Clinical Summary
A 10-year-old, otherwise healthy, boy presented with a 1.5-week history of a painless swelling on the right dorsal chest wall. Clinically, it was a firm, slightly mobile mass, not adherent to the overlying skin but fixed to the muscle. On magnetic resonance imaging an intramuscular lobulated lesion in the serratus anterior muscle was seen, measuring 24 × 12 × 22 mm. The lesion showed slightly high signal intensity compared to the surrounding muscles on T1-weighted images and moderately high signal intensity on T2-weighted images. Hypointensity of the tumor border was observed in both T1-weighted and T2-weighted images. The mass extended along the superficial fascia of the muscle (fascial tail sign). Positron emission tomography scan localized the metabolic activity. After a core needle biopsy was
taken, yielding a diagnosis of pleomorphic sarcoma possibly
leiomyogenic in type, wide resection including the deep
fascia of the serratus anterior muscle and part of the latissi-
mus dorsi muscle was performed. The tumor was
completely removed with oncological margins. No adjuvant
therapy was administered. Follow-up was performed every 3
months and the patient underwent annual computed tomog-
raphy scanning and chest X-ray on the right chest wall. In
the most recent follow-up, 22 months after surgery, the
child had no subjective symptoms including pain and
there was no sign of recurrence or metastasis.

**Material and Methods**

The tissue was fixed in 4% buffered formalin, routinely
processed, and embedded in paraffin; 2 to 4 µm thick sec-
tions were stained with hematoxylin and eosin and immu-
nohistochemistry was performed using standard protocols
and commercially available antibodies.

Fluorescence in situ hybridization (FISH) was previ-
ously reported by Bekers et al.,11 whereas Archer Fusion

Plex (Sarcoma Panel) was used analogously to Lam
et al.,12 RNA sequencing and DNA clustering analysis
were described by Karanian et al.13 DNA methylation pro-
file was performed as published by Koelsche et al.14

**Figure 1.** Low magnification shows a high cellular, infiltrative,
and well-circumscribed soft tissue lesion.

**Figure 2.** High magnification illustrates fascicular growth and
pronounced pleomorphism.

**Figure 3.** Atypical mitoses are frequent.

**Figure 4.** Smooth muscle actin (SMA) expression is
inconsistent.

**Figure 5.** By USP6–FISH, a break-apart signal indicating
rearrangement was shown.
Abbreviations: USP6, ubiquitin-specific protease 6;
FISH, fluorescence in situ hybridization.
A next-generation sequencing (NGS) cancer hotspot panel as described by de Leng et al\textsuperscript{15} was additionally used.

**Pathological Findings**

The core needle biopsy revealed a pleomorphic tumor with a fascicular growth pattern. The atypical cells had enlarged, irregular, and vesicular nuclei with prominent nucleoli. Mitotic figures were numerous including atypical forms. Osteoclast-like giant cells were seen, scattered throughout. The resection specimen showed a relatively circumscribed lesion incompletely surrounded by a collagenous pseudo-capsule. Histology was similar to the biopsy. In addition, there was focally peripheral ossification and hemosiderin deposition throughout the lesion. Vascular invasion was observed focally (Figures 1 to 3).

**Immunohistochemically**, the spindle cells were positive for smooth muscle actin (SMA) and caldesmon and negative for desmin, S100, cytokeratin MNF116, epithelial membrane antigen, and CD34 (Figure 4).

**Molecular Findings**

The methylation profile matched with NF (calibration score: 0.94). Therefore, FISH, Archer Fusion Plex (Sarcoma Panel) and RNA sequencing were performed identifying \textit{USP6} and \textit{COL6A2–USP6} fusion gene as detected by RNAseq. (A) Ten unique reads supporting the \textit{COL6A2–USP6} fusion were detected to align both at the \textit{COL6A2} (ENST00000300527) exon 1 boundary and the exon 9 boundary of \textit{USP6} (ENST00000574788). Positions on UCSC Genome Browser are shown for both genes. (B) Schema of the genomic region of \textit{COL6A2} (blue) and \textit{USP6} (red) genes. Genomic regions and positions indicated are related to the GRCh38 genome assembly.

Abbreviations: \textit{COL6A2}, collagen, type VI, alpha 2; \textit{USP6}, ubiquitin-specific protease 6.

![Figure 6.](image-url)
rearrangement (break apart signal in 49 of 100 cells) with a collagen, type VI, alpha 2 (COL6A2–USP6 (ex1–ex9) fusion (Figures 5 and 6). DNA clustering analysis (uniform manifold approximation and projection [UMAP] three-dimensional plot) of 1434 sarcoma samples in 124 molecular subgroups allocated the lesion within the NF cluster (Figure 7). An NGS cancer hotspot panel with complete coding regions of the genes F-box and WD repeat containing 7 (FBXW7), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4), SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1), Tumor protein P53 (TP53), von Hippel-Lindau tumor suppressor (VHL), and WT1 transcription factor (WT1) revealed no aberrations.

Discussion

NF usually is a benign superficially located soft tissue lesion molecularly defined by the presence of a USP6 rearrangement. Currently, several USP6 fusion partners including ribosome binding protein 1 (RRBP1), myosin heavy chain 9 (MYH9), calumenin (CALU), catenin beta 1 (CTNNB1), MIR22 host gene (MIR22HG), secreted protein acidic and cystein rich (SPARC), thrombospondin 2 (THBS2), and COL6A2 are known and their number is still growing due to improved molecular techniques.

USP6 fusions also occur in other nonmalignant soft tissue and bone abnormalities such as myositis ossificans, fibro-osseous pseudotumor of the digits, a subset of fibromas of the tendon sheath, possibly better classified as NF, primary aneurysmal bone cyst, and giant-cell tumors of the small bones. All these lesions probably form a spectrum of one entity called USP6-associated neoplasms. As our lesion was intramuscularly situated and showed focally ossification one could argue whether this case better could be classified as myositis ossificans. However, this is clinically not of relevance.

The current available comprehensive molecular analysis allowed us to make the diagnosis of NF in a histomorphological pleomorphic sarcoma-like lesion in a child. We identified for NF known COL6A2–USP6 fusion.

Figure 7. Uniform manifold approximation and projection (UMAP) analysis represented nodular fasciitis cases in red and our case in black.
Also, methylation profiling and DNA-clustering analysis were consistent with NF. Furthermore, we did not find secondary genetic changes using a NGS oncology panel. To our knowledge, this is the first NF case showing pleomorphism with bizarre nuclei and atypical mitotic figures, not in concordance with the classical morphology of NF. However, the lesion behaved benignly like ordinary NF cases.

In the literature, we encountered two cases with malignant clinical course.9,10 In contrast to our case, both showed classical histologic features of NF and a PPP6R3–USP6 fusion with additional amplification suggesting that this specific amplified fusion gene is causative for the aggressive clinical course of the disease. One of these cases was characterized by multiple recurrences and metastatic behavior whereas the other case showed aggressive growth with local invasion.9,10

In summary, we present a soft tissue tumor in a child with morphological features of a high-grade sarcoma but with molecular characteristics of NF representing the first case of a morphologically malignant NF, albeit with benign clinical features.

This case illustrates that the morphology of soft tissue tumors does not predict per se clinical behavior and genetic analysis is of added value to get a better insight into the morphological spectrum of an entity. The latter can help to avoid over- or undertreatment.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval
Confirm that all the research meets the ethical guidelines, including adherence to the legal requirements of the study country.

Informed Consent
Informed consent was obtained.

Trial Registration
Not applicable, because this article does not contain any clinical trials.

ORCID iDs
Simone ter Horst https://orcid.org/0000-0003-4849-5826
Uta Flucke https://orcid.org/0000-0003-0315-4307

References
1. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. International Agency for Research on Cancer; 2020.
2. Luna A, Molinari L, Bollea Garlatti LA, et al. Nodular fasciitis, a forgotten entity. Int J Dermatol. 2019;58:190-193.
3. Gibson TC, Bishop JA, Thompson LD. Parotid gland nodular fasciitis: a clinicopathologic series of 12 cases with a review of 18 cases from the literature. Head Neck Pathol. 2015;9:334-344.
4. Chemnman J. Nodular fasciitis in the tongue—a mimicker of malignancy: case report and review of literature. Indian J Surg Oncol. 2017;8:214-216.
5. Malik F, Wang L, Yu Z, et al. Benign infiltrative myofibroblastic neoplasm of childhood with USP6 gene rearrangement. Histopathology. 2020;77:760-768.
6. Erickson-Johnson MR, Chou MM, Evers BR, et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 2011;91:1427-1433.
7. Paulson VA, Stojanov IA, Wasmann JK, et al. Recurrent and novel USP6 fusions in cranial fasciitis identified by targeted RNA sequencing. Mod Pathol. 2020;33:775-780.
8. Patel NR, Chrisinger JS, Demico EG, et al. USP6 activation in nodular fasciitis by promoter-swapping gene fusions. Mod Pathol. 2017;30:1577-1588.
9. Guo R, Wang X, Chou MM, et al. PPP6R3-USP6 amplification: novel oncogenic mechanism in malignant nodular fasciitis. Genes Chromosomes Cancer. 2016;55:640-649.
10. Teramura Y, Yamazaki Y, Tanaka M, et al. Case of mesenchymal tumor with the PPP6R3-USP6 fusion, possible nodular fasciitis with malignant transformation. Pathol Int. 2019;69:706-709.
11. Bikers EM, Eijkelenboom A, Grünberg K, et al. Myositis ossificans—another condition with USP6 rearrangement, providing evidence of a relationship with nodular fasciitis and aneurysmal bone cyst. Ann Diagn Pathol. 2018;34:56-59.
12. Lam SW, Cleton-Jansen AM, Cleven AH, et al. Molecular analysis of gene fusions in bone and soft tissue tumors by anchored multiplex PCR-based targeted next-generation sequencing. J Mol Diagn. 2018;20:653-663.
13. Karanian M, Kelsey A, Paindavoine S, et al. SRF-fused perivascular tumors. Am J Surg Pathol. 2016;40:1725-1735.
14. Koelsche C, Schrmpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12:498.
15. de Leng WW, Gadella-van Hooijdonk CG, Barendrecht-Smouter FA, et al. Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin embedded material. PLoS One. 2016;11:e0149405.
16. Agaram NP, LeLoarer FV, Zhang L, et al. USP6 gene rearrangements occur preferentially in giant cell reparative granulomas of the hands and feet but not in gastric location. Hum Pathol. 2014;45:1147-1152.
17. Blackburn PR, Davila JI, Jackson RA, et al. RNA sequencing identifies a novel USP9X-USP56 promoter swap gene fusion in a primary aneurysmal bone cyst. Genes Chromosomes Cancer. 2019;58:589-594.
18. Carter JM, Wang X, Dong J, Westendorf J, Chou MM, Oliveira AM. USP6 genetic rearrangements in cellular fibroma of tendon sheath. Mod Pathol. 2016; 29: 865-869.

19. Flucke U, Shepard SJ, Beekers EM, et al. Fibro-osseous pseudotumor of digits—expanding the spectrum of clonal transient neoplasms harboring USP6 rearrangement. Ann Diagn Pathol. 2018;35:53-55.

20. Hiemcke-Jiwa LS, van Gorp JM, Fisher C, Creytens D, van Diest PJ, Flucke U. USP6-associated neoplasms: a rapidly expanding family of lesions. Int J Surg Pathol. 2020;28:816-825.